Elevai Labs Inc (ELAB) News

Form 8-K - Current report

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the...

Elevai Labs Inc. Reports First Quarter 2024 Financial Results

NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level...

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc.Elevai Biosciences...

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

Agreement adds two drug candidates to product pipeline consisting of (i) “EL-22”, a clinical stage engineered...

Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments

Five international distribution agreements signed to dateCumulative contracted minimum purchase requirements of...

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

Taiwan is ELEVAI’s third Asian contract for exosomes distribution after adding the Philippines in August of...

Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results

Company reports record annual revenues of $1.71 Million for 2023, up 123.5% over the previous year Company...

Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market

ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers NEWPORT BEACH, CA -- March 18, 2024 -- InvestorsHub NewsWire...

ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office

NEWPORT BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ: ELAB) a medical...

ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and...

ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

NEWPORT BEACH, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ: ELAB) a medical...